A Promising Pill?

Summary

Researchers unveil promising results from a phase 1 trial of a novel oral weight loss drug, amycretin. The drug combines amylin and a GLP-1 receptor agonist, potentially offering a more convenient and effective approach to weight management. Amycretin has shown remarkable results in early trials, demonstrating significant weight loss with a tolerable safety profile.

Start with a free consultation to discover how TrueNAS can transform your healthcare data management.

** Main Story**

Okay, so, there’s some buzz around a new oral medication called amycretin, and the early results for weight loss are pretty impressive. It’s still super early days, Phase 1 trial and all, but the data presented at the European Association for the Study of Diabetes (EASD) meeting in 2024, has got people talking. Novo Nordisk is behind it, and what’s interesting is it’s a combination of amylin and a GLP-1 RA – but get this – in pill form.

Now, we all know how much more convenient oral medications can be for patients. Imagine not having to deal with injections all the time.

How Amycretin Works: A Dual Approach

So, how does it actually work? Well, it’s a dual-action kind of thing. Amycretin targets two different pathways that affect appetite and metabolism. Think of it like hitting the problem from two angles. Amylin and GLP-1 RAs both help you feel full and reduce your appetite. Plus, they have other metabolic benefits. Amylin might make you more sensitive to leptin, which is a hormone that’s key for regulating weight. And GLP-1 RAs, which you’ll find in those injectable weight-loss meds we’re already familiar with, boost insulin production. The combined effect is better insulin sensitivity, less glucagon secretion, and slower digestion. All that, combined, should help with weight loss, at least in theory. I remember reading about a similar dual-action drug a few years back, and the results were promising then, too.

The Phase 1 Trial: Impressive Results, but Early Days

Now, let’s talk about the actual trial. It involved men and women, 18 to 55, with a BMI between 25 and 39.9 – so, overweight or obese, but without diabetes and generally healthy. They got either a placebo or one of two doses of amycretin for 12 weeks. And the results? Pretty wild, actually. The group that got the lower dose (50 mg) lost an average of 10.4% of their body weight. The higher dose group lost 13.1%. That said the placebo group only saw a 1.2% reduction. What’s also interesting is that the researchers didn’t see weight loss plateauing during that 12-week period. But of course, it was a short study, so that could change with longer trials. It’s worth noting that they said that the relatively short duration of the study, may influence this observation.

Safety First: How Well Was it Tolerated?

Of course, safety is always a big question, especially with new medications. One of the main goals of the Phase 1 trial was to see how well people tolerated amycretin. The good news is, it seemed to be generally well-tolerated. The side effects that were reported were pretty much what you’d expect when targeting those receptors. No red flags, as far as I’m aware. The most common side effects were gastrointestinal issues, like decreased appetite. There were two serious adverse events reported, one being acute cholecystitis and the other diabetic ketoacidosis; however the latter case involved a participant who was later diagnosed with type 1 diabetes, suggesting it might not have been caused by the drug. I think it’s important to remember that, correlation doesn’t mean causation.

What’s Next for Amycretin?

So, what does all this mean? Well, these early results are definitely encouraging. The big advantage of amycretin is that it’s an oral medication, which could make it much more appealing to patients than current injectable options. But, it won’t stop there. Novo Nordisk is also planning on exploring subcutaneous delivery which is the administration of medication through the skin, just below the dermis and epidermis, including into the subcutaneous tissue. Imagine the possibilities, right? That said, more extensive, longer-term studies are needed to confirm these results and explore any potential long-term effects. Nevertheless, amycretin could be a game-changer in the development of oral weight-loss therapies. You know, for people who are struggling with obesity and all the health problems that come with it, this could be a huge deal.

The Bigger Picture: A Changing Landscape

It’s important to remember that amycretin is joining a field that’s already buzzing with activity. There are tons of pharmaceutical companies working on new weight-loss drugs that target different metabolic pathways. You’ve got oral GLP-1 receptor agonists like orforglipron and CT-996, and dual agonists that target both GLP-1 and GIP receptors, like VK2735. The continued R&D in this space gives me hope that we’ll eventually have better, more convenient options for people looking to manage their weight. As of March 12, 2025, amycretin is still in Phase 1. It’s availability, and ultimate success, are still to be determined. The information provided here is based on the findings of a phase 1 study and may change as further research emerges.